Merck's Latest $2.7-Billion Buy Of ArQule Brings About Precision Targeted And Diversified Approach To Cancer TherapySeeking Alpha • 12/16/19
Shares of cancer-treatment company ArQule surge 100 percent on Merck acquisitionNew York Post • 12/09/19
ArQule, Inc. (ARQL) CEO Paolo Pucci on Q3 2019 Results- Earnings Call TranscriptSeeking Alpha • 10/30/19
ArQule, Inc. (ARQL) CEO Paolo Pucci on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/07/19